Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

2.450 -0.020 (-0.81%)
Streaming Delayed Price Updated: 12:48 PM EDT, Mar 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Rezolute to Participate in the Jefferies Global Healthcare Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Why Urban Outfitters Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday? ↗
Rezolute announced topline results from the Phase 2 study of RZ402 for diabetic macular edema, showing significant improvements in macular edema and a favorable safety profile. 
Via Benzinga
News headline image
RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 ↗
RZLT stock results show that Rezolute missed analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Analyst Expectations for Rezolute's Future ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are worth checking out on Wednesday as we offer up all the latest news sending shares higher and lower this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? ↗
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year. 
Via InvestorPlace
News headline image
CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying ↗
The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
News headline image
$17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones index closed higher by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
$1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying ↗
The Dow Jones index closed lower by around 0.2% on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Potential to more than double the addressable patient population living with hypoglycemia resulting from insulin receptor over-activation (tumor hyperinsulinism) 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying ↗
The Dow Jones index closed lower by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying ↗
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Rezolute And 3 Other Penny Stocks Insiders Are Buying ↗
The Dow Jones index closed lower by more than 60 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
News headline image
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
Plans to report topline data mid-second quarter 2024 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
Dallas, Texas--(Newsfile Corp. - November 24, 2023) - Stonegate Healthcare Partners highlights a unique opportunity in its report, "Black Friday... 
Via Newsfile
News headline image
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2024 Results
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.